David Wood is a lawyer and patent agent in our Calgary office. David practices intellectual property and regulatory law. David is co-chair of the Borden Ladner Gervais Cannabis Industry Focus Group and his regulatory practice is specific to the Canadian cannabis industry.
David has advised licensed producers, pre-license entities, technology companies, and other domestic and foreign participants in the Canadian cannabis industry in relation to the
Controlled Drugs and Substances Act and its regulations, including the
Access to Cannabis for Medical Purposes Regulations (the “ACMPR”) and the
Narcotic Control Regulations (the "NCR"). David is also helping various industry participants position themselves for expected changes under Bill C-45:
An Act respecting cannabis and to amend the Controlled Drugs and Substances Act, the Criminal Code and other Acts, Eliz. II: 64-65-66 (the "Cannabis Act").
David’s intellectual property practice and experience includes:
- drafting and prosecuting patent applications;
- assessing patentability of technology, validity of patents, and infringement of patents, and other patent-related due diligence;
- multi-jurisdictional patent portfolio management; and
- patent litigation.
David has experience with chemical, biochemical, information, and mechanical technologies relating to cannabis, medical devices, imaging, oil and gas, and other industries.
During his doctoral work, David characterized a complex between DNA and metal ions using a number of biochemical and biophysical techniques, including surface plasmon resonance spectroscopy, quenching of DNA-tethered fluorophores, and ethidium-based fluorescence assays. David’s education in structural biochemistry, organic chemistry, physical chemistry, plant biochemistry, and natural products chemistry provides a strong technical background for advising clients in the Canadian cannabis industry in relation to both intellectual property and regulatory law.
In addition to his technical background, David’s understanding of the ACMPR and other applicable law, his close attention to the
Cannabis Act and Alberta's Bill 26:
An Act to Control and Regulate Cannabis, and his familiarity with the Canadian cannabis industry and its participants, each add value when advising domestic and foreign clients in relation to developing or licensing technology related to the Canadian cannabis industry.